Literature-reported formulation composition
Component: YSK12-C4 | Reported molar ratio: 85 | Role: Ionizable lipid
sales@dcchemicals.com
YSK12-C4 (YSK12-MEND)
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: Cholesterol | Reported molar ratio: 15 | Role: Sterol
Literature-reported formulation composition
Component: PEG-DMG | Reported molar ratio: 1 | Role: PEG lipid
Literature-reported formulation composition
Component: Reported ratio sum | Reported molar ratio: Not reported | Role: Original ratio retained
Reported observation
Literature-reported GAPDH mRNA silencing Maximum 96% Jurkat cells, 1–30 nM siRNA · RNAiMAX maximum 37% p. 2 (PDF p. 2), Fig. 1a
Reported observation
Literature-reported GAPDH mRNA silencing Maximum 96% THP-1 cells, 1–30 nM siRNA · RNAiMAX maximum 56% p. 2 (PDF p. 2), Fig. 1b
Reported observation
Literature-reported GAPDH mRNA silencing Maximum 91% KG-1 cells, 1–30 nM siRNA · RNAiMAX maximum 43% p. 2 (PDF p. 2), Fig. 1c
Reported observation
Literature-reported GAPDH mRNA silencing Maximum 75% NK92 cells, 1–30 nM siRNA · RNAiMAX maximum 19% p. 2 (PDF p. 2), Fig. 1d
Reported observation
Literature-reported Cytotoxicity No statistically significant cytotoxicity in Jurkat and THP-1 over the tested range; significant effects at higher doses in KG-1 and NK92 WST-1, 1–100 nM siRNA · Untreated cells p. 3 (PDF p. 3), Fig. 2
Reported observation
Non-aggregability YSK12-MEND particle size remained stable in Opti-MEM I, whereas RNAiMAX aggregated substantially under the same medium conditions. · pp. 5–6 (PDF pp. 5–6), Fig. 5.